BIODEXA (BDRX) Cuts Warrant Price to $1.05 to Raise $2.3 Million
The UK biotech induced a single holder to exercise all Series M, N and O warrants at a reduced price, issuing 2.2 million ADSs plus two replacement warrants each.
Biodexa Pharmaceuticals (BDRX) has struck a warrant inducement agreement with a single accredited investor that will bring in roughly $2.3 million in gross proceeds. Under the deal, signed on September 14, 2026, the exercise price of the holder's outstanding Series M, N and O warrants is cut to $1.05 per share, and the holder is exercising all of them.
